TECHBio-Techne
Price
+37%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: the price
Quality mixed, no red flags, demanding price, growing in the filings, the market undecided.
We manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Spatial Biology segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for protein analysis, automated western blot, and multiplexed ELISA workflows.
In the company’s own words · 10-K filed Aug 22, 2025 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Bio-Techne (TECH) reported revenue of $321M in Q4 2026 (quarter ended Jun 30, 2026), up 1.3% from the same quarter a year earlier. That came with a gross margin of 66%. For the full year FY2026, revenue was $1.22B (−0.4% year on year) and net income $182M. Its largest region in Q4 2026 was United States at $166M, 52% of the disclosed total, well ahead of EMEA Excluding UK at 25%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 23, 2026On September 23, 2026, Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), held a special meeting of shareholders (the “Special Meeting”) to consider and vote on certain proposals related to the Agreement and Plan of Merger, dated as of June 25, 2026 (as it may be amended from time to time in accordance …Shareholder vote results · Form 8-K
- Sep 14, 2026As previously disclosed, on June 25, 2026, Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Merck KGaA, Darmstadt, Germany”) and EMD Holdings NewCo …Other event · Form 8-K
- Aug 12, 2026Bio-Techne Releases Fourth Quarter Fiscal 2026 Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $321.2MThe company’s own SEC segment disclosure.
- United States$166.1M52%
- EMEA Excluding UK$80.3M25%
- China$26.9M8%
- APAC Excluding Greater China$22.1M7%
- United Kingdom$14.5M5%
- Rest Of World$11.3M4%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry